Eden vs IVIM Health (2026): prices, structure, verdict

On tirzepatide, IVIM Health↗ is cheaper: $278 versus $408 a month all-in — a $130 monthly gap, $1,560 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, IVIM Health is cheaper: $149 versus $198 a month all-in — a $49 monthly gap, $588 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Eden: the record, condensed

Start with the load-bearing figure: $408 a month, all-in, is what Eden charges for tirzepatide at the 10 mg basis. Note the shape: $348 is the number in the marketing, $408 is the number at maintenance. The $60 difference is not a fee or a trick per se — it is dose-tiered pricing doing what dose-tiered pricing does — but it means the advertised figure describes month one, not month twelve.

A required $99/month membership is part of the deal, and part of the figure above: $309 of medication plus $99 of platform equals the $408 that leaves your account. Judge the membership by what it includes, but compare on the total.

To place the number: #16 of 17 verified programs, with the floor $193/month below at NexLife↗ ($215); the approved-product yardstick (Zepbound (LillyDirect↗)) sits at $449, so the compounded case here is worth $41 a month. A year at this figure: $4,896 monthly-billed.

Eden’s semaglutide program bills $198 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Eden is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Inside that $198 sits a mandatory $99-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $99, and it is not a price anyone can actually pay, because the membership cannot be declined.

Context for that figure: it ranks #10 of 20 in the verified semaglutide index — $65/month above the floor (Oak Longevity, $133) — and sits $151 under the brand benchmark (Wegovy (NovoCare↗), $349 at maintenance). Annualized, a monthly-billed year here runs $2,376.

Operationally at Eden: shipping included; commitment membership auto-renews; cancellation membership auto-renews until cancelled; pharmacy not publicly named — ask in writing before paying; states: most states; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Eden page · visit Eden ↗

IVIM Health: the record, condensed

On tirzepatide, the number that matters at IVIM Health is $278 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. The structure is tiered: the advertised entry point is $208, but the maintenance figure — the one a full year is actually billed at — is $278. That $70 gap between the ad and the anniversary is the single most important line in this record.

A required $75/month membership is part of the deal, and part of the figure above: $203 of medication plus $75 of platform equals the $278 that leaves your account. Judge the membership by what it includes, but compare on the total.

To place the number: #3 of 17 verified programs, with the floor $63/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $171 a month. A year at this figure: $3,336 monthly-billed.

Start with the load-bearing figure: $149 a month, all-in, is what IVIM Health charges for semaglutide at the 2.4 mg basis. The figure is quoted at maintenance without a separate teaser tier, which keeps the arithmetic honest by default.

Inside that $149 sits a mandatory $75-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $74, and it is not a price anyone can actually pay, because the membership cannot be declined.

Context for that figure: it ranks #3 of 20 in the verified semaglutide index — $16/month above the floor (Oak Longevity, $133) — and sits $200 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $1,788.

Operationally at IVIM Health: shipping included; commitment membership mandatory for duration; cancellation membership mandatory; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the IVIM Health page · visit IVIM Health ↗

Tirzepatide: the duel in full

Put the two tirzepatide figures side by side and hold them there: IVIM Health at $278, Eden at $408 — a $130 monthly spread that compounds to $1,560 over a maintenance year and $3,120 over two.

Both totals carry mandatory memberships inside them — $99 at Eden, $75 at IVIM Health — so the medication-only prices the ads may quote ($309 and $203) are both fictions no one can actually pay.

Semaglutide: the duel in full

The semaglutide arithmetic between these two is short: $149 (IVIM Health) against $198 (Eden). $49 a month sounds survivable; $588 a year is a decision.

Structure sharpens the gap: Eden’s figure is dose-flat (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill the same), while IVIM Health’s is not — so Eden’s number is a ceiling and IVIM Health’s advertised entry ($149) is a floor. Comparing a ceiling to a floor flatters the floor; this site compares maintenance to maintenance, which is the table above.

Both totals carry mandatory memberships inside them — $99 at Eden, $75 at IVIM Health — so the medication-only prices the ads may quote ($99 and $74) are both fictions no one can actually pay.

A way to feel the $130 monthly gap: over a year it funds 5.6 extra months at IVIM Health’s own rate — the difference is not decoration, it is medication. Over two years it compounds to $3,120, which is the horizon at which structural details (prepaid ladders, membership drag, dose-tier repricing) start mattering more than the sticker itself.

Run the same two programs on the committed basis: Eden $408/mo month-to-month against IVIM Health $278/mo month-to-month. The order holds: IVIM Health leads on both readings, so plan structure sharpens the verdict here rather than reversing it. Whichever basis fits your commitment level, the upfront totals above are the honest units.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Eden $1,224 monthly; IVIM Health $834 monthly — best path favors IVIM Health by $390. 6 months: Eden $2,448 monthly; IVIM Health $1,668 monthly — best path favors IVIM Health by $780. 12 months: Eden $4,896 monthly; IVIM Health $3,336 monthly — best path favors IVIM Health by $1,560. 24 months: Eden $9,792 monthly; IVIM Health $6,672 monthly — best path favors IVIM Health by $3,120.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Eden $594 vs IVIM Health $447 — $147 to IVIM Health. 6 mo: Eden $1,188 vs IVIM Health $894 — $294 to IVIM Health. 12 mo: Eden $2,376 vs IVIM Health $1,788 — $588 to IVIM Health. 24 mo: Eden $4,752 vs IVIM Health $3,576 — $1,176 to IVIM Health.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Eden publishes “most states”; IVIM Health publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Eden — membership auto-renews; membership auto-renews until cancelled. IVIM Health — membership mandatory for duration; membership mandatory.

Evidence: Eden source-verified (captured 2026-08-05); IVIM Health source-verified (2026-08-05).

The pattern worth internalizing: in this market, structural honesty and price honesty travel together. Programs that publish pharmacies and state lists tend to publish real maintenance prices; programs that hide one usually hide the other.

In the full tirzepatide index these two sit at #16 and #3 of 17: between them lie 12 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #10 and #3 of 20: between them lie 6 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Eden and IVIM Health

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Eden: membership auto-renews until cancelled; IVIM Health: membership mandatory) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings